MedMira (TSX-V:MIR, StockForum), a Halifax Nova Scotia-based biotechnology firm engaged in research, development and manufacturing rapid diagnostics and technology, announced today that the company received approval to market an enriched version of its Reveal(R) rapid HIV test in Europe.
According to the news release, these new enhancements build on the fastest HIV test among all patented rapid diagnostic technologies available in Europe.
Senior Director, Global Sales and Marketing, MedMira, Kevin Jones Ph.D., commented on the achievement, “"Our improved whole blood procedure will enable users to test for HIV even more quickly, which is critical in point-of-care situations. We make advancements to our Rapid Vertical Flow Technology based on customer feedback and needs as well as industry trends.”
He then concluded, “This latest version optimizes the user experience and our redesigned cartridge and cap will be used in all of MedMira's new products that are available through our current and future sales channels.”
MedMira was in the news recently when the company granted stock options to officers and directors.
Shares gained 16.67% on the news to $0.105 per share.
Currently there are 514.4m outstanding shares with a market cap of $54.0 million.